BioVaxys Announces Appointment To Its Scientific Advisory Board

VANCOUVER,B.C.,Feb. 22,2021 --BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"),a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic products,today announced the appointment of Kartik Chandran Ph.D.,to its Scientific Advisory Board ("SAB").

Dr. Chandran is a professor of microbiology and immunology and the Harold and Muriel Block Scholar in Virology at Albert Einstein College of Medicine in New York City,where he oversees a team of researchersengaged in basic and translational research on emerging RNA virusesand investigating the molecular mechanisms of infection. Dr. Chandran's laboratory focuses on coronaviruses and filoviruses,including SARS-CoV-2,Ebola virus,and Marburg virus,and other neglected emerging viruses such as hantaviruses and Crimean-Congo hemorrhagic fever virus,and leads a multi-institutional collaboration to discover and develop potent,long-lasting antibody treatments against these viruses. Dr. Chandran received his Ph.D. in Biochemistry at the University of Wisconsin-Madison,followed by research fellowships at Harvard Medical School and Brigham and Women's Hospital prior to joining Einstein.

"We are pleased to welcome Dr. Chandran to our Scientific Advisory Board. As a leading virologist and immunologist,he will provide valuable insight as we work to advance our haptenized viral vaccine platform in targeting life-threatening viral diseases," commentedKen Kovan,President and Chief Operating Officer of BioVaxys.Kovan added,"We also share common interest in exploring synthetic antigens,either to address multiple SARS-CoV-2 variants or as part of a vaccine technology to elicit a stronger immune response for other viruses."

Dr. Chandran stated,"I look forward to assisting Biovaxys in its efforts to develop new vaccines that will prepare us for future viral outbreaks." BioVaxys has developed its vaccine technology platforms based on the established immunological concept that modifying proteins with simple chemicals called haptens makes them more visible to the immune system. The process of haptenization "teaches" a patient's immune system to recognize and make target proteins more 'visible' as foreign,thereby stimulating an immune response.

About BioVaxys Technology Corp.

Based in Vancouver,BioVaxys Technology Corp. is a British Columbia-registered,early stage biotechnology company that is developing viral and oncology vaccine platforms,as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2,the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine,and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and US OTC: LMNGF.

ON BEHALF OF THE BOARD

Signed "James Passin"

James Passin,CEO

+1 646 452 7054

Media Contacts

Nikita Sashdev

Luna PR

info@lunapr.io

Cautionary Statements Regarding Forward Looking Information

This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements,other than statements of historical fact,included herein,without limitation,statements relating the future operating or financial performance of the Company,are forward looking statements. Forward-looking statements are frequently,but not always,identified by words such as "expects","anticipates","believes","intends","estimates","potential","possible",and similar expressions,or statements that events,conditions,or results "will","may","could",or "should" occur or be achieved. Forward-looking statements in this news release relate to,among other things,completion of the murine model study,regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys' vaccines,including any haptenized SARS-Cov-2 protein vaccine. There can be no assurance that such statements will prove to be accurate,and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

These forward-looking statements reflect the beliefs,opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates,primarily the assumption that BioVaxys will be successful in developing and testing vaccines,that,while considered reasonable by the Company,are inherently subject to significant business,economic,competitive,political and social uncertainties and contingencies including,primarily but without limitation,the risk that BioVayxs' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business,there are a number of risks that could affect the development of its biotechnology products,including,the need for additional capital to fund clinical trials,its lack of operating history,uncertainty about whether its products will complete the long,complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval,uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and,if so,whether its vaccine products will be commercially accepted and profitable,the expenses,delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses,financial and development obligations under license arrangements in order to protect its rights to its products and technologies,obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs,opinions,projections,or other factors,should they change,except as required by law.